Navigation Links
Henry Schein to Present at Deutsche Bank 36th Annual Health Care Conference
Date:5/2/2011

MELVILLE, N.Y., May 2, 2011 /PRNewswire/ -- Henry Schein, Inc., (NASDAQ: HSIC), the largest provider of health care products and services to office-based practitioners, announced today that Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein, and Steven Paladino, the Company's Executive Vice President and Chief Financial Officer, will present at the Deutsche Bank 36th Annual Health Care Conference on May 4, 2011. The conference is being held at The InterContinental Boston Hotel in Boston, Mass.

Henry Schein's presentation is scheduled to begin at 10 a.m. EDT and can be heard via live webcast by visiting www.henryschein.com, clicking on "Investor Relations" and following the link for "Webcasts."   A replay will be available on the Web site following the presentation.

About Henry Schein, Inc.

Henry Schein, a Fortune 500® company and a member of the NASDAQ 100® Index, is the largest provider of products and services to office-based health care practitioners.  The Company is recognized for its excellent customer service and highly competitive prices.  Henry Schein's five businesses - Dental, Medical, Animal Health, International and Technology - serve more than 700,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health practices, as well as government and other institutions.  

The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items.  Henry Schein also provides exclusive, innovative technology offerings for dental, medical and veterinary professionals, including value-added practice management software and electronic health record solutions.  Headquartered in Melville, N.Y., Henry Schein employs more than 14,000 people and has operations or affiliates in 25 countries.  The Company's net sales reached a record $7.5 billion in 2010.  For more information, visit the Henry Schein Web site at www.henryschein.com.


'/>"/>
SOURCE Henry Schein, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Henry Schein to Webcast First Quarter 2011 Conference Call Tuesday, May 3, at 10:00 a.m. EDT
2. Henry Schein Ranks #1 in Its Industry for Social Responsibility as a Fortune 2011 Worlds Most Admired Company
3. Henry Schein Establishes Matching Humanitarian Relief Fund in Response to Japan Earthquake and Tsunami
4. OHK Medical Devices Selects Henry Schein as Exclusive Distributor of HemaClear®
5. Henry Schein to Webcast Fourth Quarter 2010 Conference Call Tuesday, February 22, at 10:00 a.m. EST
6. Henry Schein to Present at the UBS 21st Annual Global Healthcare Services Conference
7. Henry Schein Completes Acquisition of Provet Holdings Limited
8. Henry Scheins 12th Annual Holiday Cheer For Children Program Encourages Volunteerism and Giving Among Team Schein Members
9. Henry Schein Reports Record Third Quarter Results
10. Henry Schein to Webcast Third Quarter 2010 Conference Call Friday, October 29, at 10:00 a.m. EDT
11. Henry Schein Inc. Donates Equipment to ADA Community Dental Health Coordinator Pilot Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... cream that’s the first in a new class of photodynamic cosmetics (PDC). , ... of skin, visibly reduce outward signs of aging, and minimize the appearance of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... targets, they rely on contracted partners to help with process innovation in drug ... combined drug formulation experience along with state-of-the-art analytical equipment in support of their ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... of predictive analytics to its patient care management module. Using this new feature, ... a patient has been initiated on continuous positive airway pressure (CPAP), oral, or ...
Breaking Medicine News(10 mins):